| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
ArsentrioxideLeukemia (acute promyelocytic)| 1 | 2008 | Arsenic trioxide: safety issues and their management. | 
| + | - | nl | Acta Pharmacol Sin 29(3):296-304 (2008) Au WY |
| 2 | 1999 | Arsenic trioxide, a novel mitochondriotoxic anticancer agent? |
| + | - | nl | J Natl Cancer Inst 91(9):743-5 (1999) |
| 3 | 2002 | Mechanisms of action of arsenic trioxide. |
| + | - | nl | Cancer Res 62(14):3893-903 (2002) |
| 4 | 2001 | Arsenic trioxide, a therapeutic agent for APL. |
| + | - | nl | Oncogene 20(49):7146-53 (2001) |
| 5 | 2004 | Arsenic trioxide: expanding roles for an ancient drug? |
| + | - | nl | Leukemia 18(9):1457-9 (2004) Ravandi F |
| 6 | 2003 | Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. |
| + | - | nl | Leukemia 17(8):1499-507 (2003) List A |
| 7 | 2005 | Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence. |
| + | - | nl | Haematologica 90(9):1231-5 (2005) Sanz MA |
| 8 | 2009 | Biological responses to arsenic compounds. |
| + | - | nl | J Biol Chem 284(28):18583-7 (2009) |
| 9 | 2002 | Molecular targets of arsenic trioxide in malignant cells. |
| + | - | nl | Oncologist 7 Suppl 1(-):14-9 (2002) |
